Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to American Journal of Obstetrics & Gynecology
Publication stageIn Press Journal Pre-Proof
The authors report no conflict of interest.
Funding source: This work was partially funded by a generous donation from the Vincent Memorial Hospital Foundation.
Presentation information: Initial data was presented as an oral presentation at the Society for Maternal Fetal Medicine’s 42nd Annual Pregnancy Meeting, January 5-February 5, 2022
Condensation: Epidural fentanyl can lead to positive maternal and neonatal peripartum toxicology tests. These tests should be interpreted with caution in patients who receive neuraxial analgesia.
AJOG at a Glance:
A. Why was this study conducted?
a. To evaluate the hypothesis that maternal fentanyl administration in neuraxial analgesia at the time of delivery leads to the presence of fentanyl in peripartum maternal and neonatal urine toxicology test results and thus may lead to false assumptions of non-prescribed use for birthing persons who have toxicology tests sent during delivery hospitalization
B. What are the key findings?
a. Fentanyl as part of neuraxial analgesia can lead to positive peripartum maternal and neonatal toxicology tests
b. Rates of positive tests vary based on timing of test in relation to epidural initiation and cessation and type of toxicology test used
C. What does this study add to what is already known?
a. This study is the first to prospectively evaluate the impact of neuraxial fentanyl on maternal and neonatal peripartum toxicology test results
b. Consideration should be given to labor analgesia as an origin of positive peripartum toxicology tests to avoid false assumptions of non-prescribed use